Focused prevention and treatment of noncommunicable diseases may reduce the burden of multimorbidity in people living with HIV who have mood disorders and multimorbidity.
A long-acting therapy may be noninferior to the current daily oral antiretroviral therapy (ART) in maintaining viral suppression in the treatment of HIV-1 infection.
Reduction in HIV-1 RNA level significantly greater for fostemsavir versus placebo in randomized cohort.
Dried blood spot viral load may be more accurate and useful than plasma viral load for patients with HIV in settings with limited resources.
Buprenorphine treatments for opioid use disorder among people living with HIV demonstrated beneficial effects in terms of viral load.
The occurrence of cardiac events in a cohort of patients with HIV was significantly higher in patients treated with tenofovir-alafenamide.
Active infection with tuberculosis enhances anti-HIV-1 antibody response.
Combination sofosbuvir/velpatasvir treatment can be highly efficacious in treating hepatitis C virus (HCV) infection in patients coinfected with HIV.
Research results revealed increased risks for cardiovascular disease and insulin resistance among young individuals with HIV.
Patients with HIV and those with a history of intravenous drug use may have significantly higher rates of hepatic steatosis, according to research results presented at the virtual Conference on Retroviruses and Opportunistic Infections, held from March 8 to 11, 2020. Two groups of researchers examined the role of hepatic steatosis across these patient populations.…
A British man, known as the London patient, may be the second person to be cured of HIV.
The transmission of direct-acting antiviral (DAA) resistance-associated substitutions (RAS) may inhibit hepatitis C virus (HCV) cure rates and elimination efforts.
Telmisartan did not affect biomarkers of central nervous system inflammation or injury when used as an adjunct to ART for acute HIV infection.
Effective 2-drug regimens may potentially decrease long-term exposure and toxicity with HIV-1 antiretroviral therapy.
Results from the DUALIS study demonstrated that dual therapy with dolutegravir and boosted darunavir tended to be an effective treatment option with no treatment-emergent resistance for people with HIV.
Dolutegravir (DTG)-based regimen may lead to significant improvement in blood lipid concentration, and no interference on glucose metabolism, but a relevant increase in trunk fat without alterations of body mass index (BMI) and body fat percent among youth with HIV. The results of this research were presented at the virtual Conference on Retroviruses and Opportunistic…
Therapy with monthly injection of long-acting cabotegravir plus rilpivirine was noninferior to once-daily oral therapy for maintaining HIV-1 suppression.
Among patients coinfected with HIV/HCV, there were no medium-term beneficial effects of sustained virologic response on markers of preclinical atherosclerosis and biomarkers of inflammation and endothelial dysfunction.
In adults with HIV aged >50 years, women have worse physical function and lower quality of life.
Greater alcohol consumption is associated with lower serum bone formation markers in patients living with HIV.